Abstract
Background Social Determinants of Health (SDoH) continue to drive persistent disparities in perioperative care. Our team has previously demonstrated racial and socioeconomic disparities in perioperative processes, notably in the administration of antiemetic prophylaxis, in several large perioperative registries. Given how neighborhoods are socially segregated in the US, we examined geospatial clustering of perioperative antiemetic disparities.
Methods We conducted a retrospective cohort study of anesthetic records from the University of Utah Hospital with 19,477 patients meeting inclusion criteria. We geocoded patient home addresses and combined them with the Census Block Group(CBG) level neighborhood disadvantage (ND), a composite index of from the National Neighborhood Data Archive (NaNDA). We stratified our patients by antiemetic risk score and calculated the number of anti-emetic interventions. We utilized Poisson Spatial Scan Statistics, implemented in SaTScan, to detect geographic clusters of under-treatment.
Results We identified one significant cluster (p < .001) of undertreated perioperative antiemetic prophylaxis cases. The relative risk (RR) of the whole cluster is 1.44, implying that patients within the cluster are 1.44 times more likely to receive fewer antiemetics after controlling for antiemetic risk. Patients from more disadvantaged neighborhoods were more likely to receive below median antiemetic prophylaxis after controlling for risk.
Conclusions To our knowledge, this is the first geospatial cluster analysis of perioperative process disparities; we leveraged innovative geostatistical methods and identified a spatially defined, geographic cluster of patients whose home address census-tract level neighborhood deprivation index predicted disparities in risk adjusted antiemetic prophylaxis.
Competing Interest Statement
Dr. Schonberger reports that he owns stock in Johnson & Johnson unrelated to the present work, and that his institution has received research support from Merck, Inc. for a study in which he participated unrelated to the present work. Dr Colquhoun reports research support paid to his institution unrelated to the present work from Merck, Inc (Rahway, NJ) and Chiesi USA (Cary, NC). Dr. Sutton is an equity option holder in US Anesthesia Partners, and a consultant for GE, Cerus, Eagle Pharmaceuticals, and Edwards Lifesciences.
Funding Statement
This study was funded from an intramural University of Utah Vice President's for Research Seed Grant (to JFP and NW) as well as partially supported by the National Institute of Health National Center for Advancing Translational Science, the National Heart Lung and Blood Institute, and the National Institute on Aging (NIH grant UL1TR004409 to MH, K08HL159327 to DAC, and R01AG059607 to RBS). The funding sources were not involved in the study design, collection, analysis and interpretation of the data, in writing the report, or in the decision to submit the article for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the University of Utah Vice President's Office.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved and considered exempt on February 9, 2023 by the Institutional Review Board at the University of Utah.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
